CircuLite’s micropump closer to EU launch with series C
This article was originally published in Clinica
Executive Summary
CircuLite, a Saddle Brook, New Jersey company developing a micropump to help circulation in severe heart failure patients, has closed its series C financing round with total commitments of $32.5m. The round, which was initiated in early 2009, was led by Forbion Capital Partners. CircuLite’s existing shareholders – Crédit Agricole Private Equity, Foundation Medical Partners, Oxford Bioscience Partners – also participated in the financing, along with several private investors. The proceeds will enable CircuLite to complete the ongoing clinical trial of its Synergy pocket micropump and gain CE marking for European commercialisation, as well as begin IDE (investigational device exemption) studies in the US. According to CircuLite, Synergy is the first implantable system designed to provide partial circulatory support for long-term use by class IIIb and early class IV heart failure patients. The company said it will be introducing a new-generation Synergy, which features enhancements resulting from its ongoing product development efforts.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.